Bluejay Diagnostics Inc
BJDXHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 3:18 PM ET
2.66-0.15 (-5.34%)
2026-11-11 21:27 CET
Market cap
3.14 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-7.27 USD m
Free cash flow, TTM
-6.24 USD m
EPS diluted, TTM
-37.96
P/E
-
Price
BJDX against its 20, 50 and 200-day averages2050200
90.5% under the 52-week high of 28.00 on 11 Nov 2025. 52-week low 1.84 on 30 Oct 2026. Last 15 sessions, 57.5% high to low
Volume 0.05× normal · the line is the 50-bar volume average
Profile
BJDX52-week range, 3% of the way up
1.8428.00
Bluejay Diagnostics, Inc. operates as a diagnostic company. It develops and markets minimally invasive point-of-care diagnostics tests and devices that provide patients and providers with access to affordable and timely healthcare. It focuses on the infectious disease, inflammation, and oncology markets. The company was founded by Svetlana Dey and Indranil Dey on March 20, 2015 and is headquartered in Acton, MA.
| Employees | 6 |
|---|---|
| IPO | Nov 10, 2021 |
| Beta | 0.86 |
| ATR, 14d | 0.31 |
| Rel volume | 0.05 |
| Inst own | 6.13% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 2.97M |
| Enterprise Value | -6.55M |
| Income | -7.27M |
| Sales | 0.00M |
| Book/sh | 18.98 |
| Cash/sh | 8.59 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 6 |
| IPO | Nov 10, 2021 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | - |
| P/B | 0.14 |
| P/C | 0.31 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | - |
| Quick Ratio | 4.64 |
| Current Ratio | 4.64 |
| Debt/Eq | 0.01 |
| LT Debt/Eq | 0.00 |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | -37.96 |
|---|---|
| EPS next Y | - |
| EPS next Q | - |
| EPS this Y | - |
| EPS next Y | - |
| EPS next 5Y | - |
| EPS past 3/5Y | 89.89% 65.04% |
| Sales past 3/5Y | - - |
| EPS Y/Y TTM | 93.91% |
| Sales Y/Y TTM | - |
| EPS Q/Q | 80.19% |
| Sales Q/Q | - |
| Earnings | Aug 13 BMO |
| EPS/Sales Surpr. | - - |
Ownership
| Insider Own | - |
|---|---|
| Insider Trans | - |
| Inst Own | 6.13% |
| Inst Trans | - |
| ROA | -81.07% |
| ROE | -98.89% |
| ROIC | -77.21% |
| Gross Margin | - |
| Oper. Margin | - |
| Profit Margin | - |
| SMA20 | 7.58% |
| SMA50 | -14.17% |
| SMA200 | -62.00% |
| Trades | - |
Technical
| Shs Outstand | 0.50M |
|---|---|
| Shs Float | - |
| Short Float | - |
| Short Ratio | 0.06 |
| Short Interest | 0.02M |
| 52W High | 28.00 -90.50% |
| 52W Low | 1.84 44.50% |
| Volatility | 14.75% 12.21% |
| ATR (14) | 0.31 |
| RSI (14) | 49.38 |
| Beta | 0.86 |
| Rel Volume | 0.05 |
| Avg Volume | 328.45K |
| Volume | 15,158 |
Performance
| Perf Week | 16.16% |
|---|---|
| Perf Month | -20.10% |
| Perf Quarter | -37.26% |
| Perf Half Y | -62.64% |
| Perf YTD | -75.08% |
| Perf Year | -90.39% |
| Perf 3Y | -99.99% |
| Perf 5Y | -100.00% |
| Perf 10Y | - |
| Recom | 3.00 |
| Target Price | 204800.00 |
| Prev Close | 2.81 |
| Price | 2.66 |
| Change % | -5.34% |
Peers
Mkt capInsider trading
7 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner | Jul 09 '26 | Buy | 1.51 | 64,047 | 96,711 | 126,993 | Jul 13 03:14 PM |
| HRT FINANCIAL LP | 10% Owner | Jul 10 '26 | Sale | 1.40 | 34,938 | 48,913 | 92,055 | Jul 13 03:14 PM |
| Wurth Douglas Clark | Director | Mar 14 '26 | Buy | 2.00 | 12,500 | 25,000 | 12,608 | May 18 05:21 PM |
| Dey Indranil | President and CEO | Mar 14 '26 | Buy | 2.00 | 12,500 | 25,000 | 12,522 | May 18 05:20 PM |
| CHASE DONALD R | Director | Mar 14 '26 | Buy | 2.00 | 12,500 | 25,000 | 12,525 | May 18 05:20 PM |
| ZEIDMAN FRED S | Director | Mar 14 '26 | Buy | 2.00 | 12,500 | 25,000 | 12,500 | May 18 05:19 PM |
| Dey Svetlana | Director | Mar 14 '26 | Buy | 2.00 | 12,500 | 25,000 | 12,501 | May 18 05:18 PM |
News
latest 14 of 144- Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split (ACCESSWIRE)
- Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness (ACCESSWIRE) +5.06%
- Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock (ACCESSWIRE) +6.50%
- Bluejay Diagnostics Federal Healthcare Partnership Builds Commercial Pathway Ahead of FDA Clearance (InvestorsHub) +23.74%
- Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets (GlobeNewswire)
- Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony IL-6 Toward Regulatory Submission and Commercialization (GlobeNewswire)
- Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study (GlobeNewswire)
- Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -9.43% +8.96%
- Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +100.00%
- Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership (GlobeNewswire)
- Bluejay Diagnostics Provides First Quarter 2026 Corporate Update (GlobeNewswire) -5.49%
- Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial (GlobeNewswire)
- Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting (GlobeNewswire)
- Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook (GlobeNewswire)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2023Q3 | 2023-11-09 | -13,312 | - | -4,928 | 0.00 | - | - |
| 2023Q2 | 2023-08-16 | -17,600 | -4,736 | -17,600 | 0.00 | 0.00 | 2 |
| 2023Q1 | 2023-05-10 | -768 | -384 | -15,955 | - | 0.81 | 1 |
| 2022Q4 | 2023-03-20 | -704 | 256 | -15,116 | - | - | 1 |
| 2022Q3 | 2022-11-09 | -960 | -512 | -18,801 | - | - | 1 |
| 2022Q2 | 2022-07-27 | -640 | -512 | -12,306 | 0.25 | - | 1 |
| 2022Q1 | 2022-04-21 | -640 | -704 | -12,795 | - | - | 1 |
| 2021Q4 | 2022-03-10 | -576 | - | -9,295 | - | - | - |
| 2021Q3 | 2021-12-16 | - | - | -7,832 | - | - | - |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2021FY | -0.840 | - | -22,200 | - | - |
| 2022FY | -58,880 | - | -58,880 | 0.25 | - |
| 2023FY | -26,624 | -26,624 | -58,098 | - | 0.00 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2023Q4 | S | 2023-12-02 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-29 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-27 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-26 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-25 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-22 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-21 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-20 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-19 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-18 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-15 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-14 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-13 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2023Q4 | S | 2023-11-12 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
Estimate history
| EPS, annual | -8266.24 | -11678.72 | -22200.32 | -59016.96 | -58098.368 | -1826.98 | -61.005 | -37.9627 | |
|---|---|---|---|---|---|---|---|---|---|
| Period | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | |
| EPS, quarterly | -4098.616 | -124.064 | -423.241 | -53.845 | -22.569 | -16.235 | -9.461 | -7.797 | -4.471 |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
| Sales, annual | 0 | 0 | 0 | 0.249 | 0 | 0 | 0 | 0 | |
| Period | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | |
| Sales, quarterly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
| Shares, annual | 0 | 0 | 0 | 0 | 0 | 0.035 | 0.151 | 0.496 | |
| Period | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ | |
| Shares, quarterly | 0.003 | 0.022 | 0.035 | 0.035 | 0.093 | 0.102 | 0.151 | 0.259 | 0.496 |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.18 | 0.17 | 0.20 | 0.78 | 0.35 | 0.15 | 0.16 | 0.14 |
| Gross Profit | -0.18 | -0.17 | -0.20 | -0.78 | -0.10 | -0.15 | -0.16 | -0.14 |
| Selling, General and Administrative Excl. Other | 7.18 | 6.78 | 6.97 | 9.53 | 9.21 | 3.08 | 1.04 | 1.49 |
| Research and Development | 3.62 | 3.05 | 3.47 | 5.71 | 4.15 | 1.15 | 0.53 | 0.45 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -7.36 | -6.95 | -7.17 | -10.31 | -9.32 | -3.23 | -1.20 | -1.63 |
| Interest Expense | - | 0.00 | 0.82 | - | - | 0.37 | 0.03 | - |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | -0.01 | -0.06 | -0.01 |
| Net Income Before Taxes | -7.27 | -6.85 | -7.72 | -9.95 | -9.30 | -3.49 | -1.16 | -0.82 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -7.27 | -6.85 | -7.72 | -9.95 | -9.30 | -3.49 | -1.16 | -0.82 |
| Net Income From Continuing Operations | -7.27 | -6.85 | -7.72 | -9.95 | -9.30 | -3.49 | -1.16 | -0.82 |
| Net Income | -7.27 | -6.85 | -20.94 | -9.95 | -9.30 | -3.49 | -1.16 | -0.82 |
| EPS (Recurring) | -13.98 | -61.01 | -1,826.98 | -58,098.39 | -57,962.28 | -22,265.89 | -12,099.76 | -8,336.17 |
| EPS (Basic, Before Extraordinaries) | -37.96 | -61.01 | -1,826.98 | -58,098.37 | -59,016.96 | -22,200.32 | -11,678.72 | -8,266.24 |
| EPS (Diluted) | -37.96 | -61.01 | -1,826.98 | -58,098.37 | -59,016.96 | -22,200.32 | -11,678.72 | -8,266.24 |
| EBITDA | -7.18 | -6.78 | -6.97 | -9.53 | -9.01 | -3.08 | -1.04 | -1.49 |
| Non-Operating Income (Expense) | 0.10 | 0.11 | 0.27 | 0.36 | 0.26 | 0.09 | 0.01 | 0.80 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | -0.00 | 6E-06 | 0.02 | 0.19 | 0.43 | 0.07 | 0.01 | 0.01 |
| Price To Sales Ratio | - | - | - | - | 30.76 | - | - | - |
| Gross Margin | - | - | - | - | -41.87 | - | - | - |
| Operating Margin | - | - | - | - | -3,741.48 | - | - | - |
| Net Margin | - | - | - | - | -3,733.11 | - | - | - |
| Shares Outstanding | 0.50 | 0.15 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Market Capitalization | 3.14 | 3.14 | 2.70 | 1.51 | 7.66 | 51.49 | 50.90 | - |
Income statement, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.05 | 0.05 | 0.05 | 0.03 | 0.04 | 0.05 | 0.04 | 0.05 |
| Gross Profit | -0.05 | -0.05 | -0.05 | -0.03 | -0.04 | -0.05 | -0.04 | -0.05 |
| Selling, General and Administrative Excl. Other | 2.30 | 1.89 | 1.41 | 1.59 | 1.95 | 1.84 | 1.45 | 1.31 |
| Research and Development | 1.44 | 0.81 | 0.59 | 0.79 | 0.89 | 0.78 | 0.55 | 0.55 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.35 | -1.94 | -1.46 | -1.62 | -1.99 | -1.89 | -1.48 | -1.36 |
| Interest Expense | - | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.19 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -2.32 | -1.92 | -1.43 | -1.60 | -1.96 | -1.86 | -1.43 | -1.48 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -2.32 | -1.92 | -1.43 | -1.60 | -1.96 | -1.86 | -1.43 | -1.48 |
| Net Income From Continuing Operations | -2.32 | -1.92 | -1.43 | -1.60 | -1.96 | -1.86 | -1.43 | -1.48 |
| Net Income | -2.32 | -1.92 | -1.43 | -1.60 | -1.96 | -1.86 | -14.66 | -1.48 |
| EPS (Recurring) | -4.47 | -7.79 | -9.46 | -16.23 | -22.57 | -53.85 | -423.24 | -124.07 |
| EPS (Basic, Before Extraordinaries) | -4.47 | -7.80 | -9.46 | -16.23 | -22.57 | -53.85 | -423.24 | -124.06 |
| EPS (Diluted) | -4.47 | -7.80 | -9.46 | -16.23 | -22.57 | -53.85 | -423.24 | -124.06 |
| EBITDA | -2.30 | -1.89 | -1.41 | -1.59 | -1.95 | -1.84 | -1.45 | -1.31 |
| Non-Operating Income (Expense) | 0.03 | 0.02 | 0.03 | 0.02 | 0.03 | 0.02 | -0.09 | 0.07 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | 0.00 | - | 0.00 |
| Shares Outstanding | 0.50 | 0.26 | 0.15 | 0.10 | 0.09 | 0.03 | 0.03 | 0.02 |
| Market Capitalization | 3.14 | 1.90 | 1.61 | 2.49 | 2.57 | 2.07 | 2.70 | 2.26 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 5.16 | 4.30 | 2.21 | 10.11 | 19.05 | 0.91 | 0.10 |
| Short Term Receivables | 0.00 | 0.01 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.12 |
| Other Current Assets | 0.30 | 0.58 | 0.71 | 1.67 | 1.61 | 0.06 | 0.08 |
| Total Current Assets | 5.46 | 4.90 | 2.96 | 11.79 | 20.66 | 1.06 | 0.30 |
| Net Property, Plant & Equipment | 1.65 | 1.72 | 1.62 | 1.70 | 0.34 | 0.46 | 0.62 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | - | - | - | - | - | 0.00 | 0.00 |
| Other Assets | 0.01 | 0.04 | 0.29 | 0.04 | 0.02 | 0.00 | 0.00 |
| Total Assets | 7.12 | 6.66 | 4.87 | 13.52 | 21.02 | 1.52 | 0.92 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.10 | 0.12 | 0.17 | 0.17 | 0.00 | 1.06 | 0.27 |
| Accounts Payable | 0.21 | 0.15 | 0.49 | 0.64 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.80 | 0.55 | 1.11 | 0.83 | 0.64 | 0.79 | 0.31 |
| Total Current Liabilities | 1.12 | 0.81 | 1.77 | 1.64 | 0.64 | 1.85 | 0.58 |
| Long Term Debt | 0.02 | 0.12 | 0.20 | 0.34 | 0.00 | 0.00 | 0.80 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.14 | 0.93 | 1.97 | 1.98 | 0.64 | 1.85 | 1.38 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.88 | 2.47 |
| Common Equity | 5.98 | 5.73 | 2.89 | 11.54 | 20.38 | -4.21 | -2.93 |
| Total Shareholders Equity | 5.98 | 5.73 | 2.89 | 11.54 | 20.38 | -0.33 | -0.46 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 5.98 | 5.73 | 2.89 | 11.54 | 20.38 | -0.33 | -0.46 |
| Total Liabilities & Stockholders Equity | 7.12 | 6.66 | 4.87 | 13.52 | 21.02 | 1.52 | 0.92 |
| Book Value Per Share | 39.54 | 165.47 | 14,951.52 | 73,077.51 | 129,714.95 | -42,412.08 | -29,568.63 |
| Tangible Book Value Per Share | 39.54 | 165.47 | 14,951.52 | 73,077.51 | 129,714.95 | -42,412.07 | -29,568.63 |
| Full-Time Employees | 6 | 7 | 10 | 16 | 9 | - | - |
| Price to Book Ratio | 0.15 | 0.47 | 0.29 | 0.55 | 2.53 | -47.09 | - |
| Return on Assets | -99.42 | -133.92 | -108.25 | -53.83 | -30.96 | -95.18 | - |
| Return on Equity | -117.02 | -178.98 | -137.90 | -58.25 | -34.79 | - | - |
| Return on Invested Capital | -114.14 | -131.99 | -321.39 | -78.25 | -17.11 | - | -241.14 |
| Quick Ratio | 4.88 | 6.05 | 1.67 | 7.19 | 32.43 | 0.53 | 0.31 |
| Current Ratio | 4.88 | 6.05 | 1.67 | 7.19 | 32.43 | 0.57 | 0.52 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY |
|---|---|---|---|---|---|---|---|---|
| Net Income | -7.27 | -6.85 | -7.72 | -9.95 | -9.30 | -3.49 | -1.16 | -0.82 |
| Depreciation | 0.18 | 0.17 | 0.20 | 0.78 | 0.31 | 0.15 | 0.16 | 0.14 |
| Other Funds (Non Cash) | 0.05 | 0.04 | 0.33 | 0.19 | 0.67 | 0.46 | -0.10 | -0.83 |
| Funds from Operations | -7.04 | -6.63 | -7.19 | -8.98 | -8.32 | -2.88 | -1.10 | -1.51 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 1.14 | 0.58 | -0.63 | 0.67 | 0.58 | -1.49 | 0.60 | -0.18 |
| Cash from Operating Activities | -5.90 | -6.05 | -7.82 | -8.31 | -7.74 | -4.37 | -0.51 | -1.69 |
| Capital Expenditures | -0.34 | -0.17 | -0.31 | -0.70 | -1.20 | -0.02 | 0.00 | -0.01 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.33 | -0.17 | -0.31 | -0.70 | -1.20 | -0.02 | 0.00 | -0.01 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 11.40 | 7.09 | 10.23 | 1.18 | 0.01 | 0.03 | 1.06 | 1.68 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 11.40 | 7.09 | 10.23 | 1.18 | 0.01 | 0.03 | 1.06 | 1.68 |
| Proceedsfrom Stock Options | -1.73 | -1.25 | -1.84 | -0.41 | -0.02 | 0.03 | 1.06 | 1.68 |
| Issuance or Reduction of Debt, Net | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 22.49 | 0.27 | -0.27 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.27 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.27 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | -0.00 | -0.06 | 0.00 | 0.00 | 0.00 | 0.10 |
| Other Financing Activities Uses | 0.00 | 0.00 | -0.00 | -0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 11.39 | 7.09 | 10.22 | 1.11 | 0.01 | 22.53 | 1.33 | 1.51 |
| Net Change in Cash | 5.16 | 0.86 | 2.09 | -7.91 | -8.93 | 18.14 | 0.82 | -0.18 |
| Free Cash Flow | -6.24 | -6.23 | -8.13 | -9.02 | -8.94 | -4.39 | -0.51 | -1.70 |
| Preferred Dividends (Cash Flow) | - | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 9.60 | 3.68 | 5.16 | 3.08 | 4.44 | 3.12 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.22 | 0.28 | 0.30 | 0.17 | 0.31 | 0.45 |
| Total Current Assets | 9.81 | 3.97 | 5.46 | 3.25 | 4.75 | 3.57 |
| Net Property, Plant & Equipment | 1.71 | 1.62 | 1.65 | 1.53 | 1.63 | 1.67 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.01 | 0.01 | 0.01 | 0.11 | 0.02 | 0.03 |
| Total Assets | 11.53 | 5.60 | 7.12 | 4.89 | 6.40 | 5.28 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.08 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 |
| Accounts Payable | 0.67 | 0.22 | 0.21 | 0.16 | 0.11 | 0.52 |
| Other Current Liabilities | 1.36 | 1.09 | 0.80 | 0.88 | 0.83 | 0.69 |
| Total Current Liabilities | 2.12 | 1.41 | 1.12 | 1.15 | 1.04 | 1.32 |
| Long Term Debt | 0.00 | 0.00 | 0.02 | 0.05 | 0.07 | 0.09 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.12 | 1.42 | 1.14 | 1.20 | 1.11 | 1.41 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 9.41 | 4.18 | 5.98 | 3.69 | 5.29 | 3.87 |
| Total Shareholders Equity | 9.41 | 4.18 | 5.98 | 3.69 | 5.29 | 3.87 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 9.41 | 4.18 | 5.98 | 3.69 | 5.29 | 3.87 |
| Total Liabilities & Stockholders Equity | 11.53 | 5.60 | 7.12 | 4.89 | 6.40 | 5.28 |
| Book Value Per Share | 18.98 | 16.16 | 39.54 | 36.05 | 56.65 | 111.66 |
| Tangible Book Value Per Share | 18.98 | 16.16 | 39.54 | 36.05 | 56.65 | 111.66 |
| Full-Time Employees | - | - | 6 | - | - | - |
| Price to Book Ratio | 0.15 | 0.46 | 0.27 | 0.67 | 0.49 | 0.53 |
| Return on Assets | -81.07 | -126.94 | -99.42 | -103.46 | -78.03 | -140.13 |
| Return on Equity | -98.89 | -171.56 | -117.02 | -126.20 | -96.69 | -200.56 |
| Return on Invested Capital | -24.68 | -45.86 | -23.83 | -42.70 | -36.49 | -47.07 |
| Quick Ratio | 4.64 | 2.81 | 4.88 | 2.83 | 4.56 | 2.71 |
| Current Ratio | 4.64 | 2.81 | 4.88 | 2.83 | 4.56 | 2.71 |
Cash flow, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Net Income | -2.32 | -1.92 | -1.43 | -1.60 | -1.96 | -1.86 |
| Depreciation | 0.05 | 0.05 | 0.05 | 0.03 | 0.04 | 0.05 |
| Other Funds (Non Cash) | 0.00 | 0.00 | 0.01 | 0.04 | -0.00 | 0.00 |
| Funds from Operations | -2.27 | -1.87 | -1.38 | -1.53 | -1.92 | -1.81 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.77 | 0.28 | -0.08 | 0.17 | -0.13 | 0.63 |
| Cash from Operating Activities | -1.50 | -1.59 | -1.45 | -1.36 | -2.05 | -1.18 |
| Capital Expenditures | -0.14 | -0.02 | -0.17 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.14 | -0.02 | -0.17 | 0.00 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 7.56 | 0.13 | 3.71 | 0.00 | 3.38 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 7.56 | 0.13 | 3.71 | 0.00 | 3.38 | 0.00 |
| Proceedsfrom Stock Options | -0.94 | 0.00 | -0.79 | 0.00 | -0.46 | 0.00 |
| Issuance or Reduction of Debt, Net | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Change in Long Term Debt | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 7.56 | 0.12 | 3.71 | -0.00 | 3.38 | -0.00 |
| Net Change in Cash | 5.91 | -1.48 | 2.08 | -1.36 | 1.33 | -1.19 |
| Free Cash Flow | -1.64 | -1.61 | -1.63 | -1.36 | -2.05 | -1.18 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | - | 0.0M | - | 775.06K |
| 2026-10-15 | 3.33% | 0.0M | 1.1M | 797.06K |
| 2026-09-30 | 3.31% | 0.0M | 1.1M | 1.39M |
| 2026-09-15 | 3.03% | 0.0M | 1.1M | 1.40M |
| 2026-08-31 | 6.11% | 0.1M | 1.1M | 1.50M |
| 2026-08-14 | 1.19% | 0.0M | 1.1M | 1.47M |
| 2026-07-31 | 1.81% | 0.0M | 0.2M | 993.73K |
| 2026-07-15 | 60.60% | 0.1M | 0.2M | 983.19K |
| 2026-06-30 | 48.43% | 0.1M | 0.2M | 339.75K |
| 2026-06-15 | 18.85% | 0.0M | 0.2M | 317.69K |
| 2026-05-29 | 3.42% | 0.0M | 0.2M | 19.15K |
| 2026-05-15 | 0.74% | 0.0M | 0.2M | 45.28K |
| 2026-04-30 | 2.19% | 0.0M | 0.2M | 49.54K |
| 2026-04-15 | 1.88% | 0.0M | 0.2M | 56.81K |
| 2026-03-31 | 4.77% | 0.0M | 0.2M | 57.15K |
| 2026-03-13 | 6.33% | 0.0M | 0.2M | 57.62K |
| 2026-02-27 | 4.13% | 0.0M | 0.2M | 47.32K |
| 2026-02-13 | 3.85% | 0.0M | 0.2M | 16.62K |
| 2026-01-30 | 6.26% | 0.0M | 0.1M | 12.35K |
| 2026-01-15 | 0.99% | 0.0M | 0.1M | 6.64K |
Option chain
expiry 2026-11-11| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | SCHEDULE 13G/A | SEC | ||
| 2026-11-04 | 8-K | Current report | 2026-10-30 | SEC |
| 2026-10-13 | 8-K | Current report | 2026-10-13 | SEC |
| 2026-10-06 | 8-K | Current report | 2026-10-06 | SEC |
| 2026-09-08 | 8-K | Current report | 2026-09-01 | SEC |
| 2026-08-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-17 | SEC |
| 2026-08-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-17 | SEC |
| 2026-08-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-17 | SEC |
| 2026-08-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-17 | SEC |
| 2026-08-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-17 | SEC |
| 2026-08-14 | SCHEDULE 13G | SEC | ||
| 2026-08-13 | SCHEDULE 13G | SEC | ||
| 2026-08-13 | 8-K | Current report | 2026-08-13 | SEC |
| 2026-08-12 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-08-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-07-22 | 8-K | Current report | 2026-07-21 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-21 | SEC |
| 2026-07-22 | 3 | Initial statement of beneficial ownership of securities | 2026-07-20 | SEC |
| 2026-07-13 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-09 | SEC |
| 2026-07-13 | 3 | Initial statement of beneficial ownership of securities | 2026-07-09 | SEC |
| 2026-07-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-08 | SEC |
| 2026-07-10 | 3 | Initial statement of beneficial ownership of securities | 2026-07-07 | SEC |
| 2026-06-26 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-06-26 | 424B3 | SEC | ||
| 2026-06-17 | S-3 | Registration statement for specified transactions by certain issuers including face-amount certificate companies | SEC | |
| 2026-06-09 | 8-K | Current report | 2026-06-09 | SEC |
| 2026-06-08 | 8-K | Current report | 2026-06-02 | SEC |
| 2026-06-05 | SCHEDULE 13G | SEC | ||
| 2026-06-02 | SCHEDULE 13D/A | SEC | ||
| 2026-06-02 | SCHEDULE 13D/A | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 96.71K | 1 | 48.91K | 1 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 125.00K | 5 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| ARMISTICE CAPITAL, LLC | 12.66% |
| HEIGHTS CAPITAL MANAGEMENT, INC | 3.42% |
| BOOTHBAY FUND MANAGEMENT, LLC | 2.62% |
| BANK OF AMERICA CORP /DE/ | 1.00% |
| VANGUARD FIDUCIARY TRUST CO | 0.99% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.89% |
| StoneX Group Inc. | 0.40% |
| Tower Research Capital LLC | 0.18% |
| UBS Group AG | 0.01% |
| L1 Global Manager Pty Ltd | 0.01% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Extended Market Index Fund | 0.89% |
| Fidelity Series Total Market Index Fund | 0.00% |
OakChart. BJDX. Cached 15 minutes.
Some panels did not load: ratings.